Neurocrine Biosciences, Inc.
NASDAQNBIX heads into the week with an interesting split: Goldman Sachs reinstated coverage with a Buy and a $213 target on the same day the stock fell nearly 4%. The analyst activity has been firmly bullish. Goldman's reinstatement on June 2 — setting a target 38% above the closing price of $154.84 — arrived alongside a broader pattern of Street upgrades. Bernstein initiated at…
NBIX short interest surges 21.8% in one week to 5.3% of float, as stock rallies ahead of earnings.
Snapshot as of 22 Jun 2026
NBIX heads into the week with an interesting split: Goldman Sachs reinstated coverage with a Buy and a $213 target on the same day the stock fell nearly 4%. The analyst activity has been firmly bullish. Goldman's…
NBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction. The…
Neurocrine Biosciences heads into its May 5 Q1 results with a notable and accelerating build in short positions — the most distinctive feature of the current setup. Short interest has climbed sharply over the past…
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NBIX — free to start on ORTEX.
Sign up for free →Open NBIX on ORTEX